首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   46555篇
  免费   2650篇
  国内免费   171篇
耳鼻咽喉   681篇
儿科学   1095篇
妇产科学   964篇
基础医学   8037篇
口腔科学   969篇
临床医学   3798篇
内科学   8479篇
皮肤病学   1405篇
神经病学   4801篇
特种医学   2186篇
外科学   7010篇
综合类   284篇
一般理论   33篇
预防医学   2395篇
眼科学   1103篇
药学   3016篇
中国医学   25篇
肿瘤学   3095篇
  2021年   456篇
  2020年   385篇
  2019年   668篇
  2018年   793篇
  2017年   611篇
  2016年   808篇
  2015年   891篇
  2014年   1146篇
  2013年   1609篇
  2012年   2246篇
  2011年   2419篇
  2010年   1587篇
  2009年   1506篇
  2008年   2485篇
  2007年   2604篇
  2006年   2415篇
  2005年   2555篇
  2004年   2361篇
  2003年   2300篇
  2002年   2388篇
  2001年   827篇
  2000年   737篇
  1999年   795篇
  1998年   573篇
  1997年   516篇
  1996年   438篇
  1995年   478篇
  1994年   416篇
  1993年   368篇
  1992年   529篇
  1991年   520篇
  1990年   436篇
  1989年   443篇
  1988年   404篇
  1987年   352篇
  1986年   376篇
  1985年   379篇
  1984年   346篇
  1983年   294篇
  1982年   282篇
  1981年   258篇
  1980年   197篇
  1979年   225篇
  1978年   230篇
  1977年   202篇
  1976年   201篇
  1974年   189篇
  1973年   196篇
  1933年   180篇
  1932年   187篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible.  相似文献   
3.
European Journal of Epidemiology - Existing research has found adverse short-term effects of the COVID-19 pandemic on mental health, but longer-term effects have been less documented. Using newly...  相似文献   
4.
5.
Zumel-Marne  Angela  Kundi  Michael  Castaño-Vinyals  Gemma  Alguacil  Juan  Petridou  Eleni Th  Georgakis  Marios K.  Morales-Suárez-Varela  Maria  Sadetzki  Siegal  Piro  Sara  Nagrani  Rajini  Filippini  Graziella  Hutter  Hans-Peter  Dikshit  Rajesh  Woehrer  Adelheid  Maule  Milena  Weinmann  Tobias  Krewski  Daniel  ′t Mannetje  Andrea  Momoli  Franco  Lacour  Brigitte  Mattioli  Stefano  Spinelli  John J.  Ritvo  Paul  Remen  Thomas  Kojimahara  Noriko  Eng  Amanda  Thurston  Angela  Lim  Hyungryul  Ha  Mina  Yamaguchi  Naohito  Mohipp  Charmaine  Bouka  Evdoxia  Eastman  Chelsea  Vermeulen  Roel  Kromhout  Hans  Cardis  Elisabeth 《Journal of neuro-oncology》2020,147(2):427-440
Journal of Neuro-Oncology - We used data from MOBI-Kids, a 14-country international collaborative case–control study of brain tumors (BTs), to study clinical characteristics of the tumors in...  相似文献   
6.
7.
ABSTRACT

Fine and ultra-fine particulate matter (PM) are major constituents of urban air pollution and recognized risk factors for cardiovascular diseases. This review examined the effects of PM exposure on vascular tissue. Specific mechanisms by which PM affects the vasculature include inflammation, oxidative stress, actions on vascular tone and vasomotor responses, as well as atherosclerotic plaque formation. Further, there appears to be a greater PM exposure effect on susceptible individuals with pre-existing cardiovascular conditions.  相似文献   
8.
IntroductionThe free radial forearm (FRFA) flap is universally still considered as the gold standard technique in penile reconstruction. Typically, a considerably large flap is required, often involving almost the entire circumference of the forearm. Partial necrosis may occur at the distal-most (dorsoradial) part of the flap as a result of insufficient perfusion.AimTo describe a new technique using the posterior interosseous artery (PIOA) to supercharge FRFA phalloplasty.MethodsIn a 12-month period, all patients having FRFA flap phalloplasty were enrolled. Perioperative, after complete flap dissection, an indocyanine green perfusion scan was performed. In case of insufficient perfusion at the distalmost part of the flap, a supramicrosurgical anastomosis was performed between the FRFA pedicle and the PIOA (artery only).Main Outcome MeasuresStudied outcomes included the rate of marginal necrosis, surgical time, postoperative posterior interosseous nerve damage and urethral complications (fistula, stenosis or necrosis).ResultsA total of 27 FRFA flap phalloplasties was performed. Anastomosis of the PIOA was needed in 15 cases. No marginal necrosis was observed in these cases. There were no cases of postoperative posterior interosseous nerve damage. There were no significant differences in urethral complications (fistula, stenosis or necrosis) between the 2 groups.Clinical ImplicationsIn selected cases where insufficient perfusion of the dorsoradial part of the flap is present, patients may benefit from arterial supercharging to prevent postoperative marginal necrosis.Strength & LimitationsStrengths include a single surgeon, thus lending continuity of skill and technique, a consecutive series, and 100% short-term follow-up. Limitations include single institution series and a limited number of patients.ConclusionArterial supercharging is effective in improving perfusion of large FRFA flaps used in phalloplasty when dorsoradial hypoperfusion is detected on an indocyanine green perfusion scan. It is a technically challenging addition to the standard technique because of the small size of the vessels, the close relationship between the PIOA and the posterior interosseous nerve, and the vulnerability of the newly constructed intra-flap anastomosis.De Wolf E, Claes K, Sommeling CE, et al. Free Bipedicled Radial Forearm and Posterior Interosseous Artery Perforator Flap Phalloplasty. J Sex Med 2019;16:1111–1117.  相似文献   
9.
10.

Background

Although alcohol is a leading risk factor for osteonecrosis of the femoral head (ONFH) and its prevalence reportedly ranges from 20% to 45%, there are no unified classification criteria for this subpopulation. In 2015, Association Research Circulation Osseous decided to develop classification criteria for alcohol-associated ONFH.

Methods

In June of 2017, Association Research Circulation Osseous formed a task force to conduct a Delphi survey. The task force invited 28 experts in osteonecrosis/bone circulation from 8 countries. Each round of the Delphi survey included questionnaires, analysis of replies, and feedback reports to the panel. After 3 rounds of the survey, consensus was reached on the classification criteria. The response rates for the 3 Delphi rounds were 100% (round 1), 96% (round 2), and 100% (round 3).

Results

The consensus on the classification criteria of alcohol-associated ONFH included the following: (1) patients should have a history of alcohol intake >400 mL/wk (320 g/wk, any type of alcoholic beverage) of pure ethanol for more than 6 months; (2) ONFH should be diagnosed within 1 year after alcohol intake of this dose; and (3) patients should not have other risk factor(s).

Conclusion

ARCO-established classification criteria to standardize clinical studies concerning AA-ONFH.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号